Akima T, Tamano M, Yamagishi H, Kubota K, Fujimori T, Hiraishi H. Surgical treatment of HCC in a patient with lamivudine-resistant hepatitis B cirrhosis with adefovir dipivoxil. World J Hepatol 2010; 2(8): 318-321 [PMID: 21161015 DOI: 10.4254/wjh.v2.i8.318]
Corresponding Author of This Article
Masaya Tamano, Professor, Department of Gastroenterology, Dokkyo Medical University Koshigaya Hospital, 2-1-50 Minami-Koshigaya, Koshigaya-Shi, Saitama 343-8555, Japan. firstname.lastname@example.org
Article-Type of This Article
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Takashi Akima, Hideyuki Hiraishi, Department of Gastroenterology, Dokkyo Medical University, Tochigi 321-0293, Japan
Masaya Tamano, Department of Gastroenterology, Dokkyo Medical University Koshigaya Hospital, Saitama 343-8555, Japan
Hidetsugu Yamagishi, Takahiro Fujimori, Department of Surgical and Molecular Pathology, Dokkyo Medical University, Tochigi 321-0293, Japan
Keiichi Kubota, Second Department of Surgery, Dokkyo Medical University, Tochigi 321-0293, Japan
Author contributions: Akima T and Tamano M did the research of this project and wrote the case report; Yamagishi H and Fujimori T did the pathological examinations; Kubota K did the hepatectomy; and Hiraishi H is the head of Department of Gastroenterology.
Correspondence to: Masaya Tamano, Professor, Department of Gastroenterology, Dokkyo Medical University Koshigaya Hospital, 2-1-50 Minami-Koshigaya, Koshigaya-Shi, Saitama 343-8555, Japan. email@example.com
Telephone: +81-48-965-1111 Fax: +81-48-965-1169
Received: April 16, 2010 Revised: July 1, 2010 Accepted: July 8, 2010 Published online: August 27, 2010
We describe a 77-year-old woman with chronic hepatitis B who became resistant to lamivudine. She was started on adefovir (10 mg daily) while still continuing lamivudine therapy. Four mo later her liver function improved and serum Hepatitis B virus (HBV)-DNA level became undetectable. Three years after the start of additional adefovir treatment, hepatocellular carcinoma (HCC) was detected and the patient underwent a successful hepatectomy. Our findings suggest that the addition of adefovir to ongoing lamivudine therapy cannot completely suppress hepatocarcinogenesis, but is useful for improving liver function in patients with lamivudine-resistant HBV-related cirrhosis, allowing HCC surgery.